Date: 2013-09-19
Type of information: Private placement
Company: Biomay (Austria)
Investors: existing shareholders
Amount: €5 million
Funding type: private placement and loan
Planned used: The fresh capital will be employed for seamless clinical development of the grass pollen allergy vaccine BM32, and the preclinical evaluation of the pipeline products for house dust mite, cat, ragweed and birch allergies.
Others:
Therapeutic area: Allergic diseases - Immunological diseases